Table 4 Baseline characteristics before and after propensity score matching for 5-flurouracil versus capecitabine
Before propensity score matching | After Propensity Score Matching | ||||||||
|---|---|---|---|---|---|---|---|---|---|
Baseline conditions | Combined N = 10,614 | 5-flurouracil n = 7,366 | capecitabine n = 3,248 | SMD | p value | Combined N = 6,486 | 5-flurouracil n = 3,243 | capecitabine n = 3,243 | SMD |
Sex (female), n(%) | 4,492(42.3%) | 3,160(42.9%) | 1,332(41.0%) | -0.37 | 0.07 | 2,645(40.8%) | 1,313(40.5%) | 1,332(41.1%) | 0.01 |
Age (years), mean ± SD | 61.8+/-10.9 | 62.9+/-10.7 | 59.2+/-10.9 | -0.34 | < 0.001* | 59.2+/-11.1 | 59.3+/-11.2 | 59.2+/-10.9 | -0.01 |
Hypertension, n(%) | 3,271(30.8%) | 2,601(35.3%) | 670(20.6%) | -0.36 | < 0.001* | 1,300(20.0%) | 630(19.4%) | 670(20.7%) | 0.03 |
Diabetes mellitus n(%) | 1,582(14.9%) | 1,228(16.7%) | 354(10.9%) | -0.18 | < 0.001* | 712(11.0%) | 358(11.0%) | 354(10.9%) | -0.00 |
Chronic kidney disease, n(%) | 15(0.14%) | 1(0.01%) | 14(0.43%) | 0.06 | < 0.001* | 15(0.23%) | 1(0.03%) | 14(0.43%) | 0.06 |
Atrial fibrillation n(%) | 193(1.82%) | 148(2.01%) | 45(1.39%) | -0.05 | 0.02* | 92(1.42%) | 47(1.45%) | 45(1.39%) | -0.01 |
Myocardial infarction n(%)# | 91(0.86%) | 75(1.02%) | 16(0.49%) | -0.07 | 0.008* | 36(0.56%) | 20(0.62%) | 16(0.49%) | -0.03 |
Ischemic stroke n(%) | 218(2.05%) | 176(2.39%) | 42(1.29%) | -0.10 | < 0.001* | 78(1.20%) | 36(1.11%) | 42(1.30%) | 0.02 |
Heart failure hospitalization n(%) | 75(0.71%) | 53(0.72%) | 22(0.68%) | -0.01 | 0.90 | 43(0.66%) | 21(0.65%) | 22(0.68%) | 0.00 |
Deep vein thrombosis n(%) | 58(0.55%) | 38(0.52%) | 20(0.62%) | 0.01 | 0.57 | 36(0.56%) | 16(0.49%) | 20(0.62%) | 0.02 |
Pulmonary embolism n(%) | 45(0.42%) | 34(0.46%) | 11(0.34%) | -0.02 | 0.42 | 27(0.42%) | 16(0.49%) | 11(0.34%) | -0.03 |